📰 Acerta Astrazeneca News
Acerta Astrazeneca News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Acerta Astrazeneca. Real-time updates on events, politics, business and more.
April 20, 2023
Experts discuss treatment options for patients with relapsed chronic lymphocytic leukemia.
December 19, 2022
The second-generation Brutons tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study in patients with chronic lymphocytic leukemia (CLL) .
December 13, 2022
NEW ORLEANS — Zanubrutinib significantly prolonged PFS compared with ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, results of the phase 3 ALPINE study showed.The second-generation Bruton tyrosine kinase (BTK) inhibitor also had a better safety profile than ibrutinib (Imbruvica; Pharmacyclics, Janssen), particularly with